A novel mouse model of chronic Pseudomonas aeruginosa infection inducing bronchiectasis-like phenotype

Abstract

Background: Given the need to translate basic research into human therapies, the development and refinement of clinically relevant animal models for bronchiectasis are critically important. To date, there are no well-established animal models for bronchiectasis. Thus, our aim was to develop a novel animal model that accurately recapitulates bronchiectasis-like pathologies.

Methods: To address this question, clinical strains of chronic Pseudomonas aeruginosa (CPA) were embedded in agar beads in vitro; then CPA-loaded agar beads and papain were repeatedly instilled intratracheally in female C57BL/6 J mice. Experimental assessments included micro-computed tomography (micro-CT) imaging, histological analysis, immune cell infiltration, cytokines, and lung function parameter measurements to evaluate structural damage, immune responses, and lung function impairments in the mouse model.

Results: In this mouse model, we observed that lung micro-CT imaging revealed significant bronchiectasis, with visible airways in the periphery, cylindrical airway expansion, and an airway-to-artery ratio > 1. Histopathology highlighted immune cell infiltration around the trachea, including lymphocytes, neutrophils, and monocytes, along with Periodic acid–Schiff staining-positive hypermucinous secretion. Compared to controls, the bronchiectasis group exhibited elevated pro-inflammatory cytokines in bronchoalveolar lavage fluid and worse lung function.

Conclusion: Our study presented a novel mouse model that better replicated the bronchiectasis-like phenotype than the CPA airway infection model, showing the advantages of the “CPA-loaded agar beads and papain”–driven approach in optimizing the disease models. The model mimicked the progression of bronchiectasis closely and could be used for studies on disease pathogenesis as well as the evaluation of novel therapies in the near future.

Keywords

bronchiectasis / micro-computed tomography (micro-CT) / mouse model / Pseudomonas aeruginosa

References

[1] Choi H, Yang B, Nam H, et al. Population-based prevalence of bronchiectasis and associated comorbidities in South Korea. Eur Respir J. 2019; 54(2):1900194.

[2] Dean SG, Blakney RA, Ricotta EE, et al. Bronchiectasis-associated infections and outcomes in a large, geographically diverse electronic health record cohort in the United States. BMC Pulm Med. 2024; 24(1): 172.

[3] Haworth CS, Shteinberg M, Winthrop K, et al. Inhaled colistimethate sodium in patients with bronchiectasis and P. aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months. Lancet Respir Med. 2024; 12(10): 787-798.

[4] Luo R, Miao X, Luo L, Mao B, Yu F, Xu J. Presence of pldA and exoU in mucoid Pseudomonas aeruginosa is associated with high risk of exacerbations in non-cystic fibrosis bronchiectasis patients. Clin Microbiol Infect. 2019; 25(5): 601-606.

[5] Chai Y, Xu J. How does Pseudomonas aeruginosa affect the progression of bronchiectasis? Clin Microbiol Infect. 2020; 26(3): 313-318.

[6] Long MB, Chotirmall SH, Shteinberg M, Chalmers JD. Rethinking bronchiectasis as an inflammatory disease. Lancet Respir Med. 2024; 12(11): 901-914.

[7] Duncan RP, Moustafa DA, Lewin GR, et al. Improvement of a mouse infection model to capture Pseudomonas aeruginosa chronic physiology in cystic fibrosis. Proc Natl Acad Sci USA. 2024; 121(33):e2406234121.

[8] Reyne N, McCarron A, Cmielewski P, Parsons D, Donnelley M. To bead or not to bead: a review of Pseudomonas aeruginosa lung infection models for cystic fibrosis. Front Physiol. 2023; 14:1104856.

[9] van Heeckeren AM, Schluchter MD. Murine models of chronic Pseudomonas aeruginosa lung infection. Lab Anim. 2002; 36(3): 291-312.

[10] Facchini M, De Fino I, Riva C, Bragonzi A. Long term chronic Pseudomonas aeruginosa airway infection in mice. J Vis Exp. 2014; 85: 51019.

[11] Hao Y, Kuang Z, Walling BE, et al. Pseudomonas aeruginosa pyocyanin causes airway goblet cell hyperplasia and metaplasia and mucus hypersecretion by inactivating the transcriptional factor FoxA2. Cell Microbiol. 2012; 14(3): 401-415.

[12] Meerburg JJ, Veerman GDM, Aliberti S, Tiddens HAWM. Diagnosis and quantification of bronchiectasis using computed tomography or magnetic resonance imaging: a systematic review. Respir Med. 2020; 170:105954.

[13] Aliberti S, Goeminne PC, O'Donnell AE, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med. 2022; 10(3): 298-306.

[14] Barré-Sinoussi F, Montagutelli X. Animal models are essential to biological research: issues and perspectives. Future Sci OA. 2015; 1(4): FSO63.

[15] Thomsen K, Kobayashi O, Kishi K, et al. Animal models of chronic and recurrent Pseudomonas aeruginosa lung infection: significance of macrolide treatment. APMIS. 2022; 130(7): 458-476.

[16] Gross P, Pfitzer EA, Tolker E, Babyak MA, Kaschak M. Experimental emphysema: its production with papain in normal and silicotic rats. Arch Environ Health. 1965; 11: 50-58.

[17] Hayashi R, Srisomboon Y, Iijima K, et al. Cholinergic sensing of allergen exposure by airway epithelium promotes type 2 immunity in the lungs. J Allergy Clin Immunol. 2024; 153(3): 793-808.

[18] Lambrecht BN. Alveolar macrophage in the driver's seat. Immunity. 2006; 24(4): 366-368.

[19] Keir HR, Shoemark A, Huang JTJ, Chalmers JD. SPLUNC1 is a novel marker of disease severity and airway infection in bronchiectasis. Eur Respir J. 2021; 58(5):2101840.

[20] Campisi R, Nolasco S, Mancuso M, et al. Eosinophilic bronchiectasis: prevalence, severity, and associated features-a cohort study. J Clin Med. 2024; 13(16): 4932.

[21] Hoyer FF, Naxerova K, Schloss MJ, et al. Tissue-specific macrophage responses to remote injury impact the outcome of subsequent local immune challenge. Immunity. 2019; 51(5): 899-914.

[22] Dagvadorj J, Shimada K, Chen S, et al. Lipopolysaccharide induces alveolar macrophage necrosis via cd14 and the p2x7 receptor leading to interleukin-1α release. Immunity. 2015; 42: 640-653.

[23] Cai B, Thorp EB, Doran AC, et al. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis. J Clin Invest. 2017; 127(2): 564-568.

[24] Louis C, Souza-Fonseca-Guimaraes F, Yang Y, et al. NK cell-derived GM-CSF potentiates inflammatory arthritis and is negatively regulated by CIS. J Exp Med. 2020; 217(5):e20191421.

[25] Ebbo M, Gérard L, Carpentier S, et al. Low circulating natural killer cell counts are associated with severe disease in patients with common variable immunodeficiency. EBioMedicine. 2016; 6: 222-230.

[26] McDonnell MJ, Anwar GA, Rutherford RM, et al. Lack of association between KIR and HLA-C type and susceptibility to idiopathic bronchiectasis. Respir Med. 2014; 108(8): 1127-1133.

[27] Yang B, Han K, Kim SH, et al. Being underweight increases the risk of non-cystic fibrosis bronchiectasis in the young population: a nationwide population-based study. Nutrients. 2021; 13(9): 3206.

[28] Lee JM, Lee SA, Han CH, et al. Body mass index as a predictor of mortality in bronchiectasis: a nationwide population-based study. Respir Med. 2021; 180:106370.

[29] Lopes AJ, Camilo GB, de Menezes SLS, Guimarães FS. Impact of different etiologies of bronchiectasis on the pulmonary function tests. Clin Med Res. 2015; 13(1): 12-19.

Rights & permissions

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.